Back to top

Image: Bigstock

Epizyme, Inc.

Read MoreHide Full Article

The company’s narrower-than-expected loss in the fourth quarter of 2015 was encouraging. With no approved products in its kitty as of yet, the company’s efforts to develop its lead candidate tazemetostat for a number of indications are also impressive. Epizyme expects 2016 to be a critical year given several data readouts lined up from its trials on tazemetostat in NHL and solid tumors. The company is also preparing for discussions with global regulatory authorities. Moreover, the company has outlined a five-year growth strategy and targets to launch tazemetostat globally for both NHL and genetically-defined solid tumors by 2020. The company expects to move at least three new oncology programs into clinical development by 2020.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Epizyme, Inc. (EPZM) - free report >>

Published in